Osteogenic differentiation induced by bone morphogenetic protein 2 and long non-coding RNA AK007000

doi:10.3969/j.issn.2095-4344.2014.15.001

Abstract

Abstract:

BACKGROUND: Long non-coding RNA (lncRNA) regulates a series of physiological processes and it is considered to play important roles in the gene regulation of development, differentiation and metabolism. MC3T3-E1, C2C12 and C3H10T1/2 cells are able to differentiate into different cell lineages, such as bone cells and muscle cells, and they can be used in the study of musculoskeletal diseases.
OBJECTIVE: To study the role of lncRNA in osteogenic differentiation induced by bone morphogenetic protein 2.
METHODS: Osteogenic differentiation of MC3T3-E1, C2C12 and C3H10T1/2 cells was induced by bone morphogenetic protein 2, and microarray expression profiling of lncRNA was undertaken in osteogenic differentiation. LncRNA simultaneous changes in three cells were found out. The siRNA interference of the lncRNA was used to study its effects on the osteogenic differentiation induced by bone morphogenetic protein 2. Real-time PCR and alkaline phosphatase staining were applied to detect osteogenesis related indicators.
RESULTS AND CONCLUSION: In the process of osteogenic differentiation induced by bone morphogenetic protein 2, osteogenic differentiation indicators were increased, while myogenic differentiation indicator myogenin was reduced. LncRNA AK007000 was screened out to play a role in osteogenic differentiation induced by bone morphogenetic protein 2. Knockdown of lncRNA AK007000 decreased the expression of osteogenic differentiation indicators, while increased the expression of myogenin. Therefore, AK007000 may play a role in promoting osteogenic differentiation and inhibiting myogenic differentiation.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: bone morphogenetic proteins, alkaline phosphatase, osteocalcin, RNA interference

CLC Number:

R318

Gao Yan, Cheng Chen, Li Jing, Zhang Yue, Xiao Wei-fan, Pan Qiu-hui. Osteogenic differentiation induced by bone morphogenetic protein 2 and long non-coding RNA AK007000[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(15): 2297-2302.

Figures/Tables 3

References

[1]Wapinski O,Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354-361.
[2]Guttman M, Amit I, Garber M,et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature.2009;458:223-227.
[3]Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci.USA. 2009;106:11667-11672.
[4]Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs.Cell.2007;129:1311-1323 .
[5]Pauli A, Rinn JL, Schier AF. Non-coding RNAs as regulators of embryogenesis. Nature Rev. Genet.2011;12:136-149.
[6]Guttman M, Rinn JL, Modular regulatory principles of large non-coding RNAs. Nature.2012;482:339-346.
[7]Cesana M,Cacchiarelli D,Legnini I,et al.A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA.Cell.2011;147:358-369.
[8]Kretz M,Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non coding RNA TINCR.Nature. 2013;493:231-235.
[9]Kretz M,Webster DE,Flockhart RJ,et al.Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev.2012;26:338-343.
[10]Ng SY, Johnson R, Stanton LW. Human long non coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. EMBO J.2011;31:522-533.
[11]Basem M,Abdallah MK.The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: Current status and future perspectives.J Cell Physiol.2009; 218:9-12.
[12]Chen D, Zhao M,Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004; 22: 233-241.
[13]Brooke G,Cook M, Blair C,et al.Therapeutic applications of mesenchymal stromal cells.Semin Cell Dev Biol.2007;18: 846–858.
[14]Tsuchida K.Targeting myostatin for therapies against muscle‐wasting disorders. Curr Opin Drug Discov Devel.2008;11(4): 487-494.
[15]Hamrick MW, Arounleut P, Kellum E,et al.Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma. 2010; 69(3):579-83.
[16]Connelly LB, Woolf A, Brooks P.Cost-effectiveness of interventions for musculoskeletal conditions. Disease control in developing countries. Oxford, U.K. Oxford University Press.2006;963-980.
[17]Connelly LB, Supangan R.The economic costs of road traffic crashes: Australia, states and territories.Accid Anal Prev.2006; 38(6):1087-93.
[18]Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res.2007; 22(3):465-475.
[19]Marks R. Hip fracture epidemiological trends, outcomes, and risk factors, 1970-2009.Int J Gen Med.2010;3:1-17.
[20]Hamrick M. JMNI special issue: basic science and mechanisms of muscle-bone interactions.J Musculoskelet Neuronal Interact.2010;10(1):1-2.